Role of Octreotide, Scopolamine Butylbromide, and Hydration in Symptom Control of Patients with Inoperable Bowel Obstruction and Nasogastric Tubes
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 19 (1) , 23-34
- https://doi.org/10.1016/s0885-3924(99)00147-5
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Octreotide in the Management of Bowel Obstruction in Terminal Ovarian CancerGynecologic Oncology, 1996
- Symptom control in terminally ill patients with malignant bowel obstruction (MBO)Journal of Pain and Symptom Management, 1994
- Octreotide in relieving gastrointestinal symptoms due to bowel obstructionPalliative Medicine, 1993
- Results of surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancerDiseases of the Colon & Rectum, 1993
- Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patientsJournal of Pain and Symptom Management, 1992
- Intestinal obstruction in patients with widespread intraabdominal malignancyJournal of Pain and Symptom Management, 1992
- Control of emesis in bowel obstruction in terminally ill patientsThe Lancet, 1992
- Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstructionJournal of Pain and Symptom Management, 1991
- Characterization of muscarinic receptor subtypes in human tissuesLife Sciences, 1988
- MEDICAL MANAGEMENT OF INTESTINAL OBSTRUCTION IN PATIENTS WITH ADVANCED MALIGNANT DISEASEThe Lancet, 1985